title: NovoPen Echo(®) insulin delivery device.
abstract: The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabetes mellitus. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. The portable and discreet nature of pen devices reduces the burden on the patient, facilitates adherence, and subsequently contributes to the improvement in glycemic control. NovoPen Echo(®) is one of the latest members of the NovoPen(®) family that has been specifically designed for the pediatric population and is the first to combine half-unit increment (=0.5 U of insulin) dosing with a simple memory function. The half-unit increment dosing amendments and accurate injection of 0.5 U of insulin are particularly beneficial for children (and insulin-sensitive adults/elders), who often require small insulin doses. The memory function can be used to record the time and amount of the last dose, reducing the fear of double dosing or missing a dose. The memory function also provides parents with extra confidence and security that their child is taking insulin at the correct doses and times. NovoPen Echo is a lightweight, durable insulin delivery pen; it is available in two different colors, which may help to distinguish between different types of insulin, providing more confidence for both users and caregivers. Studies have demonstrated a high level of patient satisfaction, with 80% of users preferring NovoPen Echo to other pediatric insulin pens.
authors.affiliation: Novo Nordisk Pharma Ltd, Tokyo, Japan.
authors.forename: Jacob
authors.initials: J
authors.lastname: Hyllested-Winge
authors.affiliation: Novo Nordisk A/S, Søborg, Denmark.
authors.forename: Thomas
authors.initials: T
authors.lastname: Sparre
authors.affiliation: Novo Nordisk A/S, Søborg, Denmark.
authors.forename: Line Kynemund
authors.initials: LK
authors.lastname: Pedersen
keywords: NovoPen Echo®; adherence; adolescents; children; half-unit increment dosing; memory function